RPTX Stock Surges to 52-Week High as Repare Therapeutics Secures $30M Polymerase Inhibitor Deal

Repare Therapeutics Inc. (RPTX) stock is rallying in pre-market trading, climbing 20.73% to $2.62 and reaching a new 52-week peak, following an announcement that marks a strategic inflection point for the precision oncology firm. This momentum reflects investor optimism around the company’s portfolio monetization strategy and strengthened cash position.

The Strategic Asset Transfer

The catalyst: Repare has finalized an agreement with Gilead Sciences, Inc. (GILD) whereby Gilead acquires the rights to RP-3467, a clinical-stage polymerase theta ATPase inhibitor. The deal structure includes $25 million upfront and a potential $5 million in milestone payments contingent on technology transfer completion, totaling $30 million in potential consideration.

RP-3467 represents a differentiated therapeutic approach, targeting polymerase theta as a synthetic lethality mechanism in patients harboring BRCA mutations and related genomic defects. The asset is progressing through the POLAR Phase 1 clinical trial, evaluating efficacy both as a monotherapy and in combination with olaparib across advanced ovarian, breast, prostate, and pancreatic cancers—a broad oncology indication set that underscores the drug’s potential commercial scope.

Significance for Repare’s Strategic Positioning

This transaction constitutes Repare’s third significant portfolio deal during 2025 and represents the most material to date. The upfront capital injection provides essential near-term liquidity runway, particularly as the company navigates its pending acquisition by Xeno Therapeutics. Following this cash infusion, revised valuations suggest Repare shareholders could receive approximately $2.20 per share upon close of the Xeno transaction.

Repare CEO Steve Forte characterized the arrangement as synergistic: “This transaction leverages Gilead’s oncology research and development capabilities with RP-3467, positioning it as a potential best-in-class polymerase theta inhibitor in the synthetic lethality space.”

Market Context and Stock Performance

The deal simultaneously validates both Gilead’s deepened commitment to oncology and synthetic lethality platforms, and Repare’s ability to extract value from its asset portfolio. RPTX has traded within a $0.89 to $2.30 range over the trailing 12 months, with today’s move representing a decisive breakout that signals market approval of the company’s strategic direction and de-risking initiatives.

The transaction underscores how clinical-stage assets in high-priority therapeutic areas can command significant valuations, even as companies undergo consolidation events.